SCHEMBL9918979

SCHEMBL9918979

Cc1ccc2c(c1)CC(=O)N(C)C2=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 2/20 0.50
SRD5A1 P18405 1/20 0.49
PARP10 Q53GL7 2/20 0.45
PARP11 Q9NR21 1/20 0.45
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
HTR2B P41595 2/20 0.44
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
GAA P10253 4/20 0.44
CASP6 P55212 2/20 0.44
TLR9 Q9NR96 1/20 0.44
APP P05067 1/20 0.44
ALDH1A1 P00352 3/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
PARP1 P09874 1/20 0.41
PDE5A O76074 1/20 0.40
ACHE P22303 1/20 0.39
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8343209 0.89 METAP1 (0.50) METAP1SRD5A1PARP10PARP11HTR2A
SCHEMBL9918982 0.81 SRD5A1 (0.50) METAP1SRD5A1PARP10HTR2AHTR2C
SCHEMBL9922266 0.81 TDP2 (0.51) SRD5A1KMT2AMEN1GAACASP6
SCHEMBL12706597 0.81 RAB9A (0.44) KMT2AMEN1GAATLR9ALDH1A1
SCHEMBL9922248 0.78 APP (0.41) KMT2AMEN1CASP6APPALDH1A1
SCHEMBL9922246 0.78 ALDH1A1 (0.60) HTR2AKMT2AMEN1GAAAPP
SCHEMBL9922257 0.78 METAP1 (0.55) METAP1HTR2AHTR2CHTR2BKMT2A
SCHEMBL5986263 0.78 HSD17B10 (0.47) METAP1SRD5A1KMT2AMEN1GAA
SCHEMBL30222138 0.78 TRIM24 (0.54) SRD5A1KMT2AMEN1GAAALDH1A1
SCHEMBL434054 0.78 TRIM24 (0.54) SRD5A1KMT2AMEN1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221405-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-08-07 US disclosed
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 METAP1 2686/4885SRD5A1 1785/4885PARP10 1155/4885
US-20140221405-A1 PLATELET ADP RECEPTOR INHIBITORS PTAFR, ADGRF1, P2RY6 METAP1 2155/4885SRD5A1 1881/4885PARP10 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.